TORONTO, Ontario — October 2, 2025 — Leads & Copy — Algae-C Inc. has issued a correction to its earlier release regarding its acquisition by Rockcliffe Labs Inc. The initial release incorrectly stated that all outstanding securities of Algae-C were exchanged for shares of Rockcliffe Labs.
The corrected information clarifies that Rockcliffe Labs acquired a controlling interest in Algae-C for cash consideration, with financial terms remaining undisclosed. Algae-C will now operate as a majority-owned subsidiary of Rockcliffe Labs. The remaining Algae-C shareholders will continue as minority shareholders of Algae-C and will not hold any equity, economic, or voting interest in Rockcliffe Labs. All other details from the earlier announcement remain unchanged.
Rockcliffe Labs’ acquisition of Algae-C involves integrating Algae-C’s operations and management into Rockcliffe Labs’ governance and reporting framework. Rockcliffe Labs acquired control through the purchase of a majority block of securities, settled in cash. Algae-C’s library of over 600 identified molecules, with pharmaceutical, nutraceutical, cosmetic, and industrial applications, will expand Rockcliffe Labs’ pipeline. The integration of Algae-C’s IP and technical expertise with Rockcliffe Labs’ infrastructure aims to create commercial opportunities and diversify Rockcliffe Labs’ portfolio.
Rockcliffe Labs plans to maintain Algae-C’s research operations, advance algae-derived molecules into development, align practices with Rockcliffe Labs’ systems, and pursue strategic partnerships. Following the acquisition, former Algae-C shareholders hold an ownership interest in Rockcliffe Labs, alongside existing shareholders and strategic partners.
Algae-C Inc. is a Canadian biotechnology company focused on algae-based molecular discovery and production, while Rockcliffe Labs Inc. is a Canadian biotechnology venture creation platform.
Media Contact Algae-C Inc. Email: media@algae-c.com
Investor Contact Algae-C Inc. Email: ir@algae-c.com
Source: Algae-C Inc.
